Coronary Artery Disease

FDA panel again rejects wider use of J&J's Xarelto

A panel of Food and Drug Administration experts again opposed expanding use of Johnson & Johnson's blood thinner Xarelto to reduce dangerous blood clots in a new group of patients, those with acute coronary artery disease.

Jan 16, 2014
popularity not rated yet | comments 0

Latest Spotlight News

Twitter helps smokers kick the habit, study finds

When subjects in a smoking cessation program tweet each other regularly, they're more successful at kicking the habit, according to a study by UC Irvine and Stanford University researchers. Specifically, ...